Volume 5, Issue 2 (volume 5, number 2 2013)                   IJDO 2013, 5(2): 88-90 | Back to browse issues page

XML Print

Effect of Bromocriptine Mesylate as Add-On Therapy in Obese Type 2 Diabetes Mellitus Patients
Rajendra Dhore , Akshay Dhore , Vinod Wasnik * , Nilesh Jadhav
MBBS, M.D. (PSM) Associate Professor, Department of Community Medicine. Dr. Panjabrao Deshmukh .Medical College, Amravati Maharashtra ,India
Abstract:   (30241 Views)
Six months administration of bromocriptine mesylate significantly decreased glycated hemoglobin (HbA1c), fasting blood sugar, postprandial blood sugar, and weight of 22 Indian obese patients with type 2 diabetes mellitus with no serious adverse events. Therefore, the novel mechanism of action, efficacy and acceptable safety profile makes this drug an attractive option for treatment of obese type 2 diabetic patients.
Keywords: T2DM, Bromocriptine mesylate, HbA1c
Full-Text [PDF 98 kb]   (1746 Downloads)    
Type of Study: Research | Subject: Special
Received: 2014/03/15 | Accepted: 2014/03/15 | Published: 2014/03/15
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.